Table 1 Participant characteristics and injection parameters.
Characteristics | Control (n = 26) | PTSD (n = 23) | p-value |
|---|---|---|---|
Age: years | 32 ± 12 | 38 ± 10 | 0.10 |
Sex | 8 F, 18 M | 10 F, 13 M | 0.36 |
Body mass index | 27.3 ± 4.3 | 27.8 ± 5.4 | 0.68 |
rs6971 Genotype | 17 HAB, 9 MAB | 18 HAB, 5 MAB | 0.32 |
Ethnicity (%) | Â | Â | 0.32 |
  African American | 6 (23) | 9 (39) |  |
  Asian/Pacific Islander | 1 (4) | 1 (4) |  |
  Caucasian | 12 (46) | 9 (39) |  |
  Hispanic | 7 (27) | 4 (17) |  |
Clinical Characteristics | |||
PTSD severity | Â | Â | Â |
  CAPS-IV (n) | — | 71 ± 24 (10) | — |
  CAPS-5 (n) | — | 32 ± 10 (13) | — |
Trauma exposure(s) | (n = 16) |  |  |
  Sexual trauma | 3 | 12 | — |
  Physical trauma | 10 | 21 | — |
  Childhood trauma | 11 | 23 | — |
  Combat | 3 | 9 | — |
  Accident/natural disaster | 13 | 17 | — |
Years since primary trauma (n) | 16 ± 10 (12) | 16 ± 11 (22) | 0.91 |
Current comorbid MDD | — | 18 | — |
Currently on psychotropic medication | — | 5 | — |
Current tobacco users | 12 | 8 | 0.41 |
Current cannabis users | 4 | 7 | 0.21 |
Current alcohol users | 17 | 13 | 0.53 |
Injection parameters | |||
 Injected dose (MBq) | 502.6 ± 189.3 | 573.9 ± 165.7 | 0.17 |
 Injected mass (µg/kg)* | 0.03 ± 0.03 | 0.01 ± 0.01 | 0.022 |
 fP | 0.024 ± 0.008 | 0.020 ± 0.007 | 0.14 |